Clinical, Economic,and Psychosocial Burden of Thalassemia in Sohag

This study aims to assess the clinical, economic, and psychosocial burden of thalassemia among affected children in Sohag. Clinically, the study will evaluate disease severity, transfusion requirements, iron overload, complications, and treatment-related factors. Economically, it will estimate direct medical costs, including transfusions, medications, investigations, hospital visits, and other healthcare expenses, as well as indirect costs such as school/work absenteeism and caregiver burden. Psychosocial aspects will include assessment of quality of life, psychological well-being, social functioning, and the impact of the disease on patients and their families.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Thalassemia Particularly Transfusion Dependent Thalassemia Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Behavior Behavioral Symptoms Congenital, Hereditary, and Neonatal Diseases and Abnormalities Financial Stress Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Stress, Psychological Thalassemia

Age range

2 year–18 year

Sex eligibility

All sexes

Study type

Observational

About this study

Thalassemia constitutes one of the most common inherited hemoglobin disorders worldwide and remains a major public health problem in Egypt, where carrier rates approach 9-10% and both alpha and beta thalassemia gene defects are well documented in the population . In Egypt, the burden of disease is particularly evident among pediatric patients with transfusion dependent beta thalassemia (TDT), who require lifelong regular blood transfusions and iron chelation therapy and are consequently at risk of iron overload, organ damage, and transfusion transmitted infections despite improvements in transfusion safety .

Regional studies from Upper Egypt have documented a high frequency of transfusion related complications in multitransfused children, including elevated rates of hepatitis C and other infections, and have highlighted ongoing gaps in screening and blood safety practices that continue to contribute to clinical morbidity . Concurrently, quality of life (QoL) research in Egyptian pediatric thalassemia populations demonstrates consistent and clinically meaningful impairments across physical, emotional, social, and school functioning domains, with socioeconomic disadvantage and markers of greater disease severity (for example, higher ferritin and longer disease duration) associated with worse outcomes .

Beyond direct clinical consequences, thalassemia imposes a substantial economic and psychosocial burden on families and health systems . Cost analyses and health resource studies indicate significant direct medical expenses and large indirect costs from caregiver absenteeism, transport, and lost productivity, and these burdens are magnified in low resource settings where comprehensive social support is limited. Cultural factors such as high rates of consanguineous marriage and variable uptake of premarital screening in Egypt also influence disease prevalence and complicate prevention strategies

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children and adolescents diagnosed with thalassemia. Age from 2 to 18 years. Regular follow-up at the selected pediatric hematology clinic or thalassemia unit

Exclusion criteria

Children with other chronic hematological disorders unrelated to thalassemia.

Children with severe acute illness at the time of data collection. Children or caregivers who refuse participation.

Treatment and study plan

Primary outcomes

Clinical burden of thalassemia

Time frame: through study completion, an average of 1 year

Clinical burden will be assessed using the frequency of hospital admissions, blood transfusion requirements, and disease-related complications among children and adolescents with thalassemia.
Economic burden of thalassemia

Time frame: through study completion, an average of 1 year

Economic burden will be assessed based on direct medical costs, including costs of medications, blood transfusions, laboratory investigations, hospitalizations, and other healthcare utilization.
Psychosocial burden of thalassemia

Time frame: through study completion, an average of 1 year

Psychosocial burden will be assessed using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales (PedsQL 4.0), Family APGAR questionnaire, and Patient Health Questionnaire-4 (PHQ-4). The PedsQL 4.0 consists of 23 items and is scored on a 0-100 scale, with higher scores indicating better health-related quality of life. The Family APGAR consists of 5 items with a total score ranging from 0 to 10, with higher scores indicating better family functioning. The PHQ-4 consists of 4 items with a total score ranging from 0 to 12, with higher scores indicating greater psychological distress. The GAD-2 and PHQ-2 subscale scores each range from 0 to 6, with higher scores indicating greater anxiety and depressive symptoms, respectively.

Study contacts

Contact information is provided by the study sponsor or research team.

Randa Alhm Hamam

CONTACT

[email protected]

01289625763

Sponsors and collaborators

Lead sponsor

Randa Elham Hamam

Other

Registry information

Official study title

The Hidden Burden of Thalassemia in Sohag Clinical Economic and Psychosocial Perspectives

Acronym: HBT-sohag

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 31, 2026
Registry last updated: Aug 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting